replication in vitro. Mother-to-child transmission (MTCT) of GBV-C has been observed in multiple small studies. Our study examined the rate and correlates of MTCT of GBV-C in a large cohort of GBV-C-HIV-coinfected pregnant women in Thailand.
but does not appear to cause disease in humans. The prevalence of GBV-C infection in the general population is higher than that of other bloodborne viruses, such as human immunodeficiency virus (HIV) and hepatitis C virus in western industrialized countries and varies globally, as does GBV-C genotype. Among antenatal populations, the prevalence of GBV-C RNA varies from 1%-2% in East Asia [1, 2] to 5%-7% in Europe, Australia, and Southeast Asia [3] [4] [5] [6] and 10%-13% in Africa [7, 8] . GBV-C infection is also more prevalent in HIV-infected persons and others with risk factors for bloodborne infections [9] and can be transmitted parenterally, sexually, and vertically [10] . Mother-to-child transmission (MTCT) of GBV-C has been hypothesized as one possible mechanism for the relatively high prevalence of GBV-C infection in the general population [4, 11, 12] .
Although GBV-C infection alone appears to have no clinical significance, MTCT of GBV-C may be important for several reasons. First, GBV-C infection has been associated with slower progression and prolonged survival in HIV-infected adults in some but not all studies [13] [14] [15] [16] [17] [18] [19] [20] [21] and has been observed to inhibit HIV replication in vitro [17] . It is therefore possible that GBV-C coinfection may also improve survival among HIVinfected infants. Second and potentially more importantly, MTCT of GBV-C was found to be associated with reduced MTCT of HIV in our larger related analysis [22] , although the biologic mechanism for this association remains unknown.
Wide variations in rates of MTCT of GBV-C (range, 13%-100%) were reported in 19 published studies that we identified [1, 2, 4, 11, 12, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . A limitation of all of these studies is their sample size, varying from 1 to 34 GBV-C-infected women. Despite small sample sizes, 3 studies identified high maternal GBV-C load, and 2 of these studies found that vaginal or emergency caesarean delivery was a risk factor for MTCT of GBV-C [1, 2, 11] . To better delineate transmission rates and risk factors for transmission, we combined data from several studies of perinatal HIV transmission in Thailand, where 20% of HIVinfected pregnant women were coinfected with GBV-C [22] . Our cohort of 245 GBV-C-HIV-coinfected pregnant women and their infants is the largest cohort to examine correlates of MTCT of GBV-C to date.
METHODS
The source population for this study consisted of 1498 nonbreast-feeding participants (enrolled before 31 March 2004) of 3 perinatal HIV transmission studies conducted jointly by the Thailand Ministry of Public Health and the US Centers for Disease Control and Prevention at 2 large Bangkok hospitals. Study 1 (1992-1994; ) was a natural history study conn p 342 ducted before the advent of antiretroviral prophylaxis (ART) for the prevention of MTCT of HIV [37] . Study 2 (1996 Study 2 ( -1998  ) was a randomized placebo-controlled trial assessing n p 397 the efficacy of short-course zidovudine prophylaxis [38] . Study 3 (1999-2004; ) was an observational study assessing n p 759 the implementation of programs to prevent MTCT of HIV [39] . Eighty-three percent of women enrolled in study 3 received zidovudine prenatally and/or at delivery, and 220 women and their infants also received nevirapine. All infants in study 3 received either zidovudine treatment or combination treatment with zidovudine and nevirapine.
Delivery blood specimens from 1440 women were available and tested for GBV-C RNA, antibody, and if the specimen was GBV-C RNA positive, genotype. Plasma specimens from the GBV-C RNA-positive women's infants at 4 or 6 months of age were tested for GBV-C RNA. For a few infants for whom 4-or 6-month specimens were not available, 2-and 12-month plasma specimens were requested. Plasma samples from 21 GBV-C RNA-positive infants from study 1 were also tested for GBV-C RNA at all other available collection times (from birth to 37 months) to assess the time of detection and clearance of GBV-C RNA in infants. Newborns had blood samples obtained directly and not from cord blood.
In the original 3 studies, specimens were collected and tested for the presence of HIV. HIV load and CD4
+ and CD8 + cell counts were measured as described elsewhere [37, 38] . Laboratory staff were blinded to patient data.
GBV-C RNA was extracted from 200 mL of plasma with use of the QIAamp MinElute Virus Vacuum kit (Qiagen) and was quantified using the Quantitect Probe reverse-transcriptase polymerase chain reaction (RT-PCR) kit (Qiagen), according to the manufacturer's instructions. The lower limit of reliable detection of this quantitative RT-PCR test is 1000 viral copies per reaction. Positive maternal samples, including 39 with 1-999 viral copies per reaction, were confirmed by genotype analysis, as described elsewhere [40, 41] .
GBV-C RNA-positive women (defined as women with a GBV-C load у1000 viral copies per reaction or 1-999 viral copies per reaction and who had specimens could be genotyped) and their infants, were included in the present study. Infants were classified into 1 of 3 mutually exclusive categories: (1) GBV-C RNA positive (GBV-C load, у1000 viral copies per reaction; detected at any age), (2) GBV-C RNA negative (GBV-C load, 0 viral copies per reaction detected in the infant specimens from 4 months of age [study 3] or 6 months of age [studies 1 and 2] or 0 viral copies per reaction found in both the 2-and 12-month infant plasma specimens), and (3) GBV-C RNA indeterminate (GBV-C load, 0-999 viral copies per reaction detected at any age or at 11 time and no specimen with a GBV-C load у1000 viral copies per reaction).
Analyses were performed using SAS (version 8.2; SAS Institute). The statistical significance of associations of maternal and infant characteristics with MTCT of GBV-C within each study was assessed with 2-sided P values from x 2 or Fisher's exact tests, using tests for trend for ordered categorical variables. Odds ratios (ORs) and 95% confidence intervals (CIs) adjusted for participants from study 1, 2, or 3 were calculated using the Cochran Mantel-Haenszel procedure for categorical variables. Homogeneity of ORs across studies was assessed with the Breslow-Day test, and the 3 studies were combined for the multivariable analysis, with a variable indicating the perinatal study included to adjust for any unmeasured confounding between studies. Variables associated with MTCT of GBV-C in the analysis adjusted for study that had a P value of !.20 were included in the analysis adjusted for study and covariates and were retained in the final model if their P value was !.05. HIV and GBV-C loads were transformed to their log 10 values. If a linear relationship was not observed, continuous variables were categorized at generally used cutoff points or at levels defined by 
Education: primary or less 52 (64) 30 (56) 59 (54) 141 (58) Commercial sex worker 10 (12.4) 7 (13) 10 (9.1) 27 (11) Birth weight !2500 g 9 (11 ) 1 (1.9) 15 (14) 25 (10) NOTE. Data are no. (%) of participants or median value (interquartile range). Study 1 was performed during 1992-1994, study 2 was performed during 1996-1997, and study 3 was performed during 1999-2004. ART, antiretroviral therapy; IDU, injection drug user.
the relationship observed with MTCT of GBV-C. Logistic regression was used to calculate ORs and 95% Wald CIs adjusted for multiple covariates. Biologically plausible interactions were assessed by adding an interaction term to the multivariable model. This study was approved by the Research Ethics Board, University of Toronto, Canada; the Institutional Review Board, Centers for Disease Control and Prevention, Atlanta; and the Ethical Review Committees for Research in Human Subjects at the Thailand Ministry of Public Health and Siriraj Hospital, Bangkok, Thailand.
RESULTS
We were able to determine GBV-C infection status for 1387 (96%) of 1440 HIV-infected pregnant women for whom delivery blood specimens were available; of these women, 274 (20%) tested positive for GBV-C RNA. Of these women, 249 had infant specimens available for testing. One hundred one (41%) of 249 infants were classified as GBV-C RNA positive, 144 (58%) of 249 were classified as GBV-C RNA negative, and 4 (2%) of 249 were classified as GBV-C RNA indeterminate. GBV-C-HIV-coinfected women and their infants with known infant GBV-C status were included in the present analysis. The 4 GBV-C RNA-indeterminate infants, one of whom was HIV infected, were not included in further analysis
The characteristics of these 245 GBV-C-HIV-coinfected women and their infants are summarized in table 1. The overall rate of MTCT of GBV-C was 41% (95% CI, 35%-48%) but was significantly different among studies (
). The rate P p .002 of MTCT of GBV-C was 26% in study 1, 54% in study 2, and Maternal GBV-C load at delivery, median copies/mL (IQR)
Maternal HIV load at delivery, median copies/mL (IQR) 46% in study 3. In study 1, we also observed significantly lower maternal GBV-C titers than in study 2 or 3 ( ).
The correlates of MTCT of GBV-C are presented in table 2. Mothers receiving ART were significantly more likely than mothers not receiving ART to transmit GBV-C to their infants (adjusted OR, 5.21 [95% CI, 2.12-12.81]; adjusted for study and covariates). The effect of maternal receipt of ART on MTCT of GBV-C was independent of GBV-C load, HIV load, and CD4 + cell count (adjusted OR 4.81 [95% CI, 1.97-11.72]). Table 3 presents rates of MTCT of GBV-C, MTCT of HIV, and maternal GBV-C and HIV load by ART regimen and study. When women did not receive ART, the rates of MTCT of GBV-C and HIV were very similar, whereas when women received ART, the rate of MTCT of HIV decreased (relative risk, 0.16;
) and the rate of MTCT of GBV-C increased (relative P ! .001 risk, 2.25;
); the ratio of MTCT of GBV-C to MTCT P ! .001 of HIV changed from 1.2 to 17.1. The rate of MTCT of GBV-C did not vary with the addition of nevirapine to zidovudine therapy ( ), and infant ART, compared with no ART, P p .36 was not associated with increased MTCT of GBV-C ( ) P p .54 GBV-C and HIV were rarely cotransmitted, and only 2 of 245 infants acquired both viruses. The rate of MTCT of GBV-C was significantly lower among HIV-infected infants than among HIV-uninfected infants (6.5% [ 
of 31 infants] vs. 46% [99 of 214];
; adjusted for study and covariates). The P ! .001 inverse association between MTCT of HIV and MTCT of GBV-C was independent of maternal receipt of ART, maternal HIV load, maternal GBV-C load, and maternal CD4 + cell count (adjusted OR, 0.06 [95% CI, 0.01-0.32]).
High maternal GBV-C load significantly increased the likelihood of MTCT of GBV-C in a dose-response relationship. There were no instances of MTCT of GBV-C detected among women with a GBV-C load !4.0 log 10 copies/mL; however, among women with a GBV-C load у8.0 log 10 copies/mL, the rate of MTCT of GBV-C was 67%. We observed no evidence of a difference in MTCT rate according to GBV-C genotypes (2, 3, or 4) in this study.
Infants born by caesarean delivery were significantly less likely to be GBV-C infected than were infants delivered vaginally ( ; adjusted for study and covariates). There was P ! .001 no statistically significant difference between rates of MTCT of GBV-C among infants delivered by elective (20% [5 of 25 infants]) and emergency caesarean delivery (33% [11 of 33]; ). No infant acquired GBV-C from mothers who had P p .43 vaginal deliveries and GBV-C loads !4 log 10 copies/mL, from mothers who had emergency cesarean deliveries and GBV-C loads !6 log 10 copies/mL, or from mothers who had elective cesarean deliveries and GBV-C loads !7 log 10 copies/mL.
Premature newborns were significantly less likely to acquire GBV-C than were full-term newborns ( ; adjusted for study), but the association P p .045 was not statistically significant in analysis adjusted for covariates in the final multivariate model. Other factors associated with an increased likelihood of MTCT of GBV-C in analysis adjusted for study but not other covariates included low maternal HIV load, high maternal CD4 + cell count, and a high CD4 + /CD8 + ratio at delivery. Male infants were slightly more likely to become GBV-C infected than were female infants in all 3 perinatal studies (48% vs. 35%; ; adjusted for study), but the P p .08 difference was of borderline significance.
Although the crude rate of MTCT of GBV-C was higher in studies 2 and 3 than in study 1, after adjusting for maternal receipt of ART, the risk of MTCT of GBV-C was not significantly different between studies (adjusted OR for study 1 vs. study 2, 1.35 [95% CI, 0.56-3.27]; adjusted OR for study 1 vs. study 3, 0.68 [95% CI, 0.27-1.73]). However, after adjusting for maternal GBV-C load and ART, women in studies 2 and 3 had a significantly lower risk of transmitting GBV-C to their infants than did women in study 1 (adjusted OR for study 1 vs. study 2, 0.22 [95% CI, 0.07-0.65]; adjusted OR for study To examine the time of GBV-C detectability and clearance in infants, we tested plasma samples from all 21 GBV-C RNApositive infants from study 1 for GBV-C RNA at all available times (figure 1). None of these infants were coinfected with HIV. Three (21%) of 14 newborn samples available for testing were positive for GBV-C RNA and 19 (95%) of 20 tested positive by 2 months. Four (50%) of 8 infants cleared virus by 36 months, but none cleared virus before 15 months of age.
DISCUSSION
Our cohort of 245 HIV-coinfected GBV-C RNA-positive mothers and their infants is the largest single cohort of GBV-Cinfected pregnant women examined to date and the first, to our knowledge, to report an association between MTCT of GBV-C and maternal ART. In our study, 41% of GBV-C-infected mothers transmitted GBV-C to their infants. This is similar to rates of MTCT of GBV-C observed in 3 smaller cohorts of HIV-coinfected women [23, 25, 26] . Maternal receipt of ART, high maternal GBV-C load, vaginal mode of delivery, and absence of infant HIV infection were independently associated with increased MTCT of GBV-C.
We observed that maternal receipt of ART increased the likelihood of MTCT of GBV-C. Of interest, Bjorkman and Widell [42] , when reviewing our previous publication [22] , noted that aggregate data presented in our manuscript pointed to an effect of ART on MTCT of GBV-C, as confirmed in the present manuscript. Because receipt of ART by neonates alone was not associated with increased rate of MTCT of GBV-C, any effect of ART appears to occur during pregnancy or at delivery. The addition of single-dose nevirapine (at delivery and to neonates) to zidovudine prophylaxis starting at 34-36 weeks of gestation also did not increase the rate of MTCT of GBV-C. There is mounting evidence that ART plays a role in both GBV-C and HIV replication and transmission. Highly active ART was associated with increased GBV-C titers and decreased HIV titers in HIV-coinfected patients in a recent study [43] ; in our study, ART was associated with increased rate of MTCT of GBV-C and decreased rate of MTCT of HIV. However, maternal GBV-C load was not significantly associated with maternal receipt of ART (after adjusting for study; data not shown). Because ART is unlikely to have affected GBV-C replication directly (a flavivirus being quite different from a retrovirus), something associated with HIV inhibition, perhaps the reduction of HIV-induced systemic immune activation [43] , may have resulted in enhanced replication and transmission of GBV-C. However, the inverse correlation that we observed between GBV-C and HIV load was quite weak [22] , and the observed association between maternal receipt of ART and in-creased rate of MTCT of GBV-C was independent of both maternal HIV and GBV-C load. Therefore, the biologic pathway for an effect of ART on MTCT of GBV-C remains unknown. ART has been associated with a reduced rate of MTCT of HIV independent of its effect on reducing HIV load [44] . Our results may suggest another potential mechanism by which maternal receipt of ART prevents MTCT of HIV, because GBV-C infection may protect against HIV infection. In support of this, HIV infection of the infant was associated with a lower rate of MTCT of GBV-C, and coinfection in the infants occurred less frequently than would be predicted if they were independent events. In the combined study, only 2 (0.8%) of 245 infants of HIV-GBV-C-coinfected mothers acquired both GBV-C and HIV at birth, whereas with perinatal transmission rates of 13% for HIV and 41% for GBV-C in our study, we might have expected 13 (5%) of 245 infants to be coinfected. Two other studies also observed a low prevalence of GBV-C infection among HIV-infected children [45, 46] ; however, we identified 3 studies of MTCT of GBV-C in HIV-infected women, and none of these studies observed a difference in cotransmission of HIV or GBV-C [23, 25, 26] . Possible reasons for the lack of association observed in these studies include small sample sizes ranging from 2 to 9 GBV-C-infected infants and different study populations. A mechanism for the strong inverse association between infant GBV-C and HIV infection that we observed remains unknown. Because both HIV and GBV-C infection appear to be vertically acquired by infants at approximately the same time [22] , it is possible that either virus may inhibit the other or that a third factor (e.g., placental inflammation, which has been associated in some studies with reduced MTCT of HIV [47] [48] [49] ) or the infant's cytokine milieu prevents coinfection with both viruses. However, because GBV-C appears to reduce replication of HIV in vitro, most strongly when the cell is infected with GBV-C first, but also when the cell is infected simultaneously with HIV and GBV-C [17] , there is a biologically plausible basis for the reduction of MTCT of HIV through infant GBV-C infection.
We confirmed observations from previous studies [1, 2, 11] that, not surprisingly, high GBV-C load and vaginal mode of delivery are associated with increased MTCT of GBV-C. Because the rate of MTCT of GBV-C was 67% at a GBV-C load of у8 log 10 copies/mL, there may not be a threshold over which transmission is 100%. However, both of the mothers with a GBV-C load of 9 log 10 viral copies/mL at delivery transmitted GBV-C to their infants (both also delivered vaginally). Although not significant, our data are consistent with elective caesarean deliveries having the lowest rate of MTCT of GBV-C, compared with other forms of delivery, as was reported in 2 other studies [1, 2] .
Risk factors associated with increased viral exposure, such as high maternal viral load and a vaginal delivery, were similar for MTCT of HIV and MTCT of GBV-C. However, risk factors commonly associated with increased MTCT of HIV (no maternal receipt of ART, high maternal HIV load, low maternal CD4 + cell count, prematurity, and female sex of the infant)
were reversed for MTCT of GBV-C. Mechanisms for this dichotomy are unknown. The timing of GBV-C transmission is unknown, but because 21% of newborn samples available for testing were positive for GBV-C RNA, in utero transmission is likely for at least some infants. The remainder were likely infected either in utero or at delivery, given that 16 (94%) of 17 tested positive at 2 months and that mode of delivery was significantly associated with MTCT of GBV-C. Our study, in which all GBV-C RNA was of genotype 2, 3, or 4, supports evidence of vertical transmission of GBV-C; however, some studies from Africa, where genotypes 1 and 5 are most prevalent [50] , have also reported evidence of horizontal transmission [24, 35] .
Our study had several limitations. Because all study participants were HIV-infected Thai women, the generalizability of our findings may be limited to certain populations or GBV-C genotypes. A limitation of studies on GBV-C in general is the lack of a gold standard test for the detection of GBV-C RNA. Although reasons for the significantly lower maternal GBV-C titers in study 1 are unknown, possible explanations may include duration of specimen storage or changes in the population or epidemiology of GBV-C over the study periods. Studies of hepatitis C virus, the closest known relative to GBV-C are suggestive of viral deterioration with long-term storage; however, the effect of duration of storage on the stability of the GBV-C has not been established. Among women who did not receive ART, the rate of MTCT of GBV-C was similar in all 3 perinatal studies (table 3) . Because viral load is a major determinant of MTCT of HIV, this might indicate that the true maternal GBV-C load in study 1 was similar to that observed in studies 2 and 3. Differences in maternal GBV-C load appear to have confounded our estimate of study differences in the rate of MTCT of GBV-C. Although positive samples from infants were not confirmed with genotype testing, only 4 indeterminate samples from infants were excluded from analysis, and this would not have affected our results.
In summary, in our cohort of GBV-C-HIV-coinfected women, GBV-C was frequently transmitted from mother to infant. Maternal receipt of ART was independently associated with increased rate of MTCT of GBV-C, although the mechanism remains unknown. We observed that high maternal GBV-C load and vaginal mode of delivery-both factors that increase the level of virus to which an infant is exposed-were associated with increased rate of MTCT of GBV-C. Despite mode of de-livery being a common risk factor, GBV-C and HIV were rarely cotransmitted.
